Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.

Ítems similars

• Enhancement of Cellular Immunity in Melanoma Patients Immunized with a Peptide from MART-1/Melan A
  per: Cormier, Janice N., et al.
  Publicat: (1997)
• Culture of Melanoma Cells in 3-Dimensional Architectures Results in Impaired Immunorecognition by Cytotoxic T Lymphocytes Specific for Melan-A/MART-1 Tumor-Associated Antigen
  per: Ghosh, Sourabh, et al.
  Publicat: (2005)
• Identification of an HLA-DPB1*0501 Restricted Melan-A/MART-1 Epitope Recognized by CD4(+) T Lymphocytes: Prevalence for Immunotherapy in Asian Populations
  per: Meng, Zhaoting, et al.
  Publicat: (2011)
• Melan-A/MART-1(51–73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
  per: Zarour, Hassane M., et al.
  Publicat: (2000)
• Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1
  per: Waterman, E A, et al.
  Publicat: (2002)